

Responding to the Needs of Patients Suffering from Neglected Diseases...









DNDi's PRIORITY:
Neglected
Patients









...from Bench to Bedside

DNDi's Mission

- To develop new drugs or new formulations of existing drugs
- To strengthen
 capacities in a
 sustainable manner
- To adopt a dynamic approach to portfolio diseases





7 new treatments delivered, recommended, implemented
















- ✓ Easy to use
- ✓ Affordable
- ✓ Field-adapted
- ✓ Non-patented

- 30 projects, 8 diseases areas
- 13 entirely new chemical entities (NCEs)
- Over 160 partnerships, most in endemic countries
- 160 staff, half in endemic countries &
 700 people working on DNDi projects
- EUR 400 million raised equally from public and private sources
- 4 regional disease-specific clinical trial platforms/ networks and several technology transfers



through innovative partnerships



Some current Japanese partners:

Eisai Takeda Shionogi Daiichi-Sankyo GeneDesign Kitasato Institute Riken Institute IMC

GHIT Fund




DNDi R&D Portfolio June 2017

7 new treatments available and up to 16 new chemical entities in the pipeline

		🗳 Research 🕒			% Translation			velopment (Implementation
	Screen	Hit to Lead	Lead Opt.	Pre-clinical	Phase I	Phase IIa/PoC	Phase IIb/III	Registration	Access
HAT			SCYX-1330682 SCYX-1608210 oxaborole			Acoziborole		Fexinidazole	NECT Nifurtimox-Eflornithine Combination Therapy
	Screening	Leish H2L	DNDI-5421 ★ DNDI-5610 oxaborole	DNDI-6148 ** oxaborole			New Treatments for HIV/VL		SSG&PM Africa
Leishmaniasis			Amino ** pyrazoles	DNDI-0690 ** nitroimidazole			New Treatments for PKDL		New VL Treatments Asia
			CGH VL * Series 1	GSK3186899 ★ DDD853651 GSK3494245 ★ DDD1305143			MF/Paromomycin Combo for Africa	New VL	Лош
				CpG-D35 (CL)		New CL Combination		Treatments Latin America	
Chagas	Screening	Chagas H2L	Chagas Lead Opt			New Benz ★ Regimens +/- fosravuconazole			Benznidazole Paediatric Dosage Form
			Biomarkers			Fexinidazole **			
Filaria	Screening		Macro * Filaricide 3	ABBV-4083 ** TylaMac	Emodepside				
Pediatric HIV					Two '4-in-1' LPV/r/ABC/3TC			LPV/r pellets with dual NRTI	Superbooster Therapy Paediatric HIV/TB
HCV							Ravidasvir/		
Mycetoma							Fosravuconazole		Malaria FDC ASAQ
	New Chemic	al Entity (NCE); Fe	xinidazole (for HAT, \	/L, and Chagas disea	se) = 1 NCE; Fosravu	iconazole = 1NCE			Malaria FDC ASMQ

DNDi R&D Portfolio June 2017


Projects with Japanese partnerships and support from the GHIT Fund providing NCEs




New Chemical Entity (NCE)

Unique compounds from Japan


- Screening of drug-like small molecules from Japanese pharmaceutical companies and research institutes
- Some interesting hits identified
- NTD Drug Discovery Booster used to accelerate these new discoveries



Japanese natural products



Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014 J Nat Prod. 2016 25;79(3):629-61



PCA plots of drugs approved by FDA between 1981–2010 parsed by compound origin


Stratton et al., 2013, Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorg Med Chem Lett. 2015 1; 25(21): 4802–4807



A BIG Experiment in Early Drug Discovery

- Drug discovery for tropical diseases such as Visceral Leishmanisais and Chagas Disease is neglected
 - Little interest, limited investment, few researchers, few tools
- Parasites are very difficult to kill
 - High Throughput Screening hit rates:
 - L. donovani (intracellular) < 0.05%
 - *T. cruzi* (intracellular) < 0.15%

Hits are scarce and precious – need to fully exploit them




THP1 cells infected with eGFP-L. donovani (courtesy of GSK Tres Cantos)


- The NTD Drug Discovery Booster Goals:
 - Expand precious HTS hits and enable scaffold-hopping to find new hits
 - Benefit from the pooling of structures and information
 - Accelerate discovery and reduce costs
 - Experiment with a new open innovation approach to drug discovery



Booster Process - Representative Example

Source	# hits		
Seed S01	1		
Partner A	~90		
Partner B	~90		
Partner C	~90		
Partner D	~40		






- Complementary compound collections and different computational approaches efficiently explore chemical space around new hits
- Rapid SAR expansion and scaffold-hopping before expensive optmimisation chemistry is needed



Booster: Progress to date





Innovative NTD Booster Project recognised by DNDi

Project of the year 2016



NTD Booster Summary



• A novel approach accelerating discovery of new drugs for NTDs



• A unique partnership of Japanese companies, the GHIT Fund and other international partners



• Diversity of chemistry and scientific approaches already yielding several promising projects



• Useful learning for growing partnership with applicability to other global health projects



- Special environment created in Japan by the GHIT Fund and Japanese pharmaceutical companies
- Global partnership committed to patients' needs
- Precious Japanese contributions to synthetic and natural compound screening, the NTD Booster, and drug discovery and development projects



Acknowledgements





Ieuan Roberts
Garry Pairaudeau
Thierry Kogej
Ola Engkvist
Duncan Young
Iain Comley
John Cuff





Benjamin Perry Charles E. Mowbray Jean-Pierre Paccaud Dominique Junod Rachel Tisseuil Rob Don Fumiko Hirabayashi Jean-Robert Ioset Leela Pavan Tadoori Daisuke Imoto Tatsuro Kuzuki Mari Matsumoto Midori Morioka



Nao-aki Watanabe Atsushi Inoue Makoto Asada Kazuya Nagaoka Mika Aoki Kunizo Higurashi Akifumi Kimura Nobuko Komura Makoto Matsui Shuichi Suzuki Kappei Tsukahara



Ryu Yoshida Rina Kaki Osamu Yoshida Chiaki Fujikoshi Aiko Yamashita Shuji Yonezawa Takashi Kawasuji Akira Naito



Mitsuyuki Shimada Yuichiro Akao Sachiko Itono Masahiro Kamaura Nobuo Cho Takashi Ichikawa Kaori Kaneko Naoki Tarui Yoshinori Ikeura Terufumi Takagi Atsuko Ochida Taisuke Tawaraishi Nao Morishita Hideki Igata



David Shum Consantin Radu Nakyung Lee

Jinyeop Kim Sooyoung Byun Hichul Kim Honggun Lee Kideok Kim Jungjin Lee









Starr International Foundation



Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra

Swiss Agency for Development and Cooperation SDC

